Sep 10, 2026 · 37 min · 15 segments
*Disseminated on behalf of* Onco-Innovations Ltd.*, may include paid advertisements.* AUSTIN, Texas, September 10, 2026 – via…
Islam MohamedGuest
Carmel FischerHost
But, you know, radiotherapy and DNA damaging chemotherapy, these remain the backbone of oncology.
The tumor can restore DNA damage and resistant subpopulations of the cancer can persist and the disease can return.
The field had recognized this a long time ago, You know, there are other possible targets in DNA damage response, and that space is pretty crowded with active programs directed at ATR or ATM or WeOne, CheckOne, PollQ.
You know, investors that are familiar with this space would be familiar with those targets as well.
But after more than a decade of investigation, PARP remains the only DNA damage response target with an approved agent in any jurisdiction.
So that's a subset of cancers that are BRCA mutant or positive for HRD for homologous repair deficiency.
So there is a considerably larger group of patients whose tumors carry common losses of tumor suppressor genes.
And the repair biology there is every bit as exploitable, but there isn't a repair-directed agent for that population of cancers.
But, you know, radiotherapy and DNA damaging chemotherapy, these remain the backbone of oncology.
The tumor can restore DNA damage and resistant subpopulations of the cancer can persist and the disease can return.
The field had recognized this a long time ago, You know, there are other possible targets in DNA damage response, and that space is pretty crowded with active programs directed at ATR or ATM or WeOne, CheckOne, PollQ.
You know, investors that are familiar with this space would be familiar with those targets as well.
But after more than a decade of investigation, PARP remains the only DNA damage response target with an approved agent in any jurisdiction.
So that's a subset of cancers that are BRCA mutant or positive for HRD for homologous repair deficiency.
So there is a considerably larger group of patients whose tumors carry common losses of tumor suppressor genes.
And the repair biology there is every bit as exploitable, but there isn't a repair-directed agent for that population of cancers.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
